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Background:  The  circumstances  surrounding  infective  endocarditis  (IE) are under  constant  change  due
to an  increase  in drug-resistant  organisms,  a decrease  in  rheumatic  valve  disease,  progress  in  surgical
treatment,  and aging  society.  The  purpose  of  this  study  was  to  compare  clinical  features  of  IE between
the  1990s  and  2000s  and  to  elucidate  the  determinants  of death  or clinical  event.
Methods:  All hospital  admission  records  between  January  1990  and  December  2009  were  retrospec-
tively  analyzed.  The  deﬁnition  of IE was  based  on  modiﬁed  Duke  criteria.  Clinical  presentation,  blood
culture,  laboratory  results,  and echocardiography  ﬁndings  were  compared  between  the 1990s  and
2000s.
Results:  There  were  112  patients  with  deﬁnite  or  probable  IE  according  to modiﬁed  Duke criteria.  The  mosturgery frequent  organism  causing  IE  was  Streptococcus  viridians  both  in  the 1990s  and  2000s.  The  determinants
of  in-hospital  death  were  hemodialysis  and  congestive  heart  failure.  The  in-hospital  mortality  of  IE  was
5.4%  in the 1990s  and  13.3%  in  the  2000s.  Composite  events  of in-hospital  death  and central  nervous
system disorders  were  signiﬁcantly  higher  in  the  2000s  compared  with  the  1990s.
Conclusion:  The  most  frequent  causative  organism  of  IE was S. viridians,  both  in  the  1990s  and  2000s.
Independent  predictors  of in-hospital  mortality  in  IE were  hemodialysis  and  congestive  heart  failure.
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The circumstances surrounding infective endocarditis (IE) are
nder constant change. In terms of the frequency of underlying
alve heart disease on the host side, a decrease in rheumatic valve
isease and increase in degenerative aortic stenosis in aging society
re reported to be changing the etiology of IE [1,2]. Regarding the
ausative organisms, an increase in intravenous drug abuse (IVDA)
rought differences among ages and countries [3]. In European
ountries and the USA, streptococci were the dominant pathogens
n the past [4–6], while recently staphylococci have been increasing
ompared with streptococci [7–11]. However, in Japan and Korea,
treptococci remain dominant [12–16]. The prevalence of new
ntibiotics and immunosuppressive drugs promoted multi-drug
esistant organisms including methicillin resistant Staphylococcus
ureus (MRSA) [8,17,18].
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In terms of the treatment, the timing of surgical intervention for
IE with embolic complications of the central nervous system (CNS)
is still controversial [19,20]. Recent prospective studies reported
that surgical treatment in the early stage of active IE was supe-
rior to conservative therapy with reduction of composite event
of all-cause death and embolic events [15,21,22]. The aim of this
study was  to elucidate the most current clinical spectrum of the
microbiology, and the relationship between surgical treatment and
in-hospital outcome of a consecutive series of patients with IE in
the 1990s and 2000s.
Methods
Study design
All hospital admission records at Saitama Medical Center, Jichi
Medical University between January 1990 and December 2009
were retrospectively reviewed for clinical presentation, blood
cultures, laboratory results, and echocardiographic ﬁndings. A
ﬂowchart of patient inclusion is shown in Fig. 1. The deﬁnition of IE
was based on modiﬁed Duke criteria [23]. The following data were
extracted: age, sex, predisposing factors, affected valves, causative
vier Ltd. All rights reserved.
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Table 2
Affected valves.
1990s (n = 37) 2000s (n = 75) p-Value
Mitral valve 28 (73.3%) 47 (62.7%) NS
Aortic valve 12 (31.6%) 33 (44%) NS
Tricuspid valve 2 (5.3%) 7 (9.3%) NS
Pulmonary valve 0 (0%) 3 (4%) NS
Multiple valves 5 (13.2%) 13 (17.3%) NS
PVE  5 (13.2%) 10 (13.3%) NS
PVE, prosthetic valve endocarditis.
Table 3
Causative microorganisms.
1990s (n = 37) 2000s (n = 75) p-Value
Streptococcus viridans 16 (43.2%) 29 (38.7%) NS
Streptococcus bovis 1 (2.7%) 3 (4%) NS
Other streptococci 1 (2.7%) 5 (6.7%) NS
HACEK group 0 (0%) 0 (0%) NS
S.  aureus 6 (16.2%) 8 (10.7%) NS
MRSA 2 (5.4%) 3 (4%) NS
Staphylococcus epidermidis 0 (0%) 3 (4%) NSFig. 1. Flow chart of patient inclusion.
icroorganisms, treatment, and outcome. These variables were
ompared between 1990–1999 (1990s) and 2000–2009 (2000s).
eﬁnition of clinical presentation
Active IE was deﬁned as on-going active infection associated
ith elevation of white blood cell count and C-reactive protein
evel and/or continuous fever. CNS disorders were deﬁned as posi-
ive ﬁndings of infarction or bleeding in computed tomography or
agnetic resonance imaging after treatment.
tatistical analysis
Statistical analysis for the comparison of data between the 2
tudy periods was performed by chi-square test or Fisher’s exact
est for categorical variables and the unpaired Student t test for
ontinuous variables. Univariate and multivariate analysis was  per-
ormed with logistic regression test using a statistics software
SPSS, Chicago, IL, USA). Signiﬁcance was deﬁned as a probability
alue of p < 0.05. Data are shown as mean ± SD.
esults
The demographic and clinical characteristics of patients are
hown in Table 1. There were 69 men  and 43 women ranging from
6 to 82 years of age. There was no signiﬁcant difference in char-
cteristics of patients between the two groups. There was  no IVDA
ither in the 1990s or 2000s. As for underlying cardiac risk fac-
ors, the percentage of prosthetic valves was not different between
able 1
atient characteristics.
1990s (n = 37) 2000s (n = 75) p-Value
Age, years 52.2 ± 14.9 54.4 ± 17.6 NS
Male 25 (67.6%) 44 (58.7%) NS
≥65  years 8 (21.6%) 27 (36.0%) NS
Diabetes mellitus 4 (10.8%) 4 (5.3%) NS
Hemodialysis 1 (2.7%) 4 (5.3%) NS
IVDA 0 (0%) 0 (0%) NS
In-hospital infection 1 (2.7%) 3 (4.0%) NS
Pre-existing VHD 7 (18.9%) 24 (32%) NS
MVP  5 (13.5%) 5 (6.7%) NS
Congenital heart disease 3 (8.1%) 6 (8%) NS
VSD 2 (5.4%) 5 (6.7%) NS
Hypertrophic cardiomyopathy 1 (2.7%) 3 (5.3%) NS
Pacemaker 0 (0%) 1 (1.3%) NS
Prosthetic valve 5 (13.2%) 10 (13.3%) NS
VDA, intravenous drug abuse; VHD, valvular heart disease; MVP, mitral valve pro-
apse; VSD, ventricular septal defect.diology 63 (2014) 145–148
the two  groups. Affected valves were similar in the two groups
(Table 2). Mitral valve was the most commonly infected through-
out the two  decades. The most frequent organism causing IE was  S.
viridians both in the 1990s and 2000s. The spectrum of organisms
causing IE had not changed signiﬁcantly in the 2000s as compared
with the 1990s (Table 3).
The clinical presentation, treatment, and outcomes are shown in
Tables 4 and 5. The surgical treatment with active IE was more fre-
quently applied in the 1900s, and the rate of embolism in CNS was
signiﬁcantly higher in the 2000s. While in-hospital death was  not
signiﬁcantly different between the two groups, composite events
of in-hospital death and CNS embolism were signiﬁcantly higher in
the 2000s than the 1990s.
The results of univariate and multivariate analysis of in-
hospital mortality are shown in Tables 6 and 7, respectively.
Age, hemodialysis, congestive heart failure, and methicillin-
resistant staphylococcal IE were signiﬁcant factors of in-hospital
mortality. Hemodialysis and congestive heart failure were inde-
pendent predictors of in-hospital mortality in multivariate
analysis.MRSE 0 (0%) 2 (2.7%) NS
Enterococcus species 4 (10.8%) 10 (13.3%) NS
Fungi 1 (2.7%) 0 (0%) NS
Others 1 (2.7%) 4 (5.3%) NS
Unknown 7 (18.9%) 13 (17.3%) NS
HACEK, haemophilus species (Haemophilus parainﬂuenzae, Haemophilus
aphrophilus, Haemophilus paraphrophilus), Actinobacillus actinomycetemcomi-
tans, Cardiobacterium hominis, Eikenella corrodens, and Kingella species. MRSA,
methicillin-resistant S. aureus; MRSE, methicillin-resistant S. epidermidis.
Table 4
Clinical ﬁndings.
1990s (n = 37) 2000s (n = 75) p-Value
Clinical presentation
Congestive heart failure 13 (34.2%) 34 (44.2%) NS
CNS disorder 3 (7.9%) 23 (29.9%) 0.006
Peripheral embolization 7 (18.4%) 17 (22.1%) NS
Echocardiographic ﬁndings
Vegetation 32 (84.2%) 65 (84.4%) NS
Abscess 3 (3.9%) 9 (11.7%) NS
Perforation 7 (18.4%) 18 (23.4%) NS
CNS, central nervous system.
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Table  5
Treatment and outcome.
1990s (n = 37) 2000s (n = 75) p-Value
Surgical treatment with active IE 18 (48.6%) 22 (29.3%) 0.037
In  hospital death 2 (5.4%) 10 (13.3%) NS
Composite events of in-hospital death and CNS disorder 5 (13.5%) 29 (38.7%) 0.006
IE, infective endocarditis; NS, not signiﬁcant; CNS, central nervous system.
Table 6
Univariate analysis of in-hospital mortality.
Factors Odds ratio (95% CI) p-Value
Age ≥65 years 3.27 (0.96–11.1) 0.048
Male 0.86 (0.25–2.90) NS
Diabetes mellitus 3.12 (0.56–17.6) NS
Hemodialysis 49.5 (4.93–497) 0.0000003
Congestive heart failure 19.56 (2.42–157) 0.00022
CNS  abnormality 2.69 (0.77–9.33) NS
Peripheral embolization 1.25 (0.31–5.05) NS
Vegetation on echocardiography 1.94 (0.23–16.2) NS
Abscess on echocardiography 0.74 (0.09–6.26) NS
Perforation on echocardiography 1.18 (0.29–4.74) NS
Prosthetic valve endocarditis 1.34 (0.26–6.81) NS
Multiple valve endocarditis 3.07 (0.82–11.6) NS
Staphylococcal IE 2.44 (0.58–10.3) NS
Methicillin-resistant staphylococcal IE 8.0 (1.54–41.5) 0.0045
Surgical treatment with active IE 0.89 (0.25–3.16) NS
CNS, central nervous system; IE, infective endocarditis; NS, not signiﬁcant.
Table 7
Multivariate analysis of in-hospital mortality.
Factors Odds ratio (95% CI) p-Value
Age ≥65 (number + 1 increase) 0.94 (0.23–3.85) 0.93
Hemodialysis (number + 100 increase) 5.30 (0.40–77.8) 0.03
Congestive heart failure (number + 100
increase)
6.60 (0.80–5.62) 0.01
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RS, methicillin-resistant staphylococci (S. aureus and S. epidermidis).
iscussion
Our study found that the most frequent causative organism of
E was S. viridians, which has not changed from the 1990s to the
000s. Composite events of in-hospital death and CNS disorders
ere signiﬁcantly higher in the 2000s compared to the 1990s. Inde-
endent predictors of in-hospital mortality were hemodialysis and
ongestive heart failure in multivariate analysis.
Previous studies from European countries reported that the
ost common causative organism was Staphylococcus. Fowler
t al. reported that the rates of causative organisms of IE were 42%
or staphylococci and 30% for streptococci [8]. Another study from
elgium reported 43% for staphylococci and 26% for streptococci
7]. However, a study from Korea reported that streptococci (45%)
ere dominant compared with staphylococci (12%) [15]. There may
e a regional difference between countries about staphylococcal
nfection with IE. Fowler et al. reported that one of the determi-
ants for infection with staphylococci was a history of IVDA [8].
n the present report, there was no IVDA patient in the 1990s or
000s in our hospital, which may  be a reason why staphylococci
ere dominant in our study.
Previous studies reported the rate of methicillin-resistant
taphylococcal infection in IE was not signiﬁcantly different
etween countries (USA 37.2%, Brazil 37.5%, Europe/Middle East
3.7%, Australia/New Zealand 15.5%, Japan 28.0%) [8,12]. The deter-
inants of infection with methicillin-resistant staphylococci were
mmunosuppressive treatment, health-care device, diabetes melli-
us, and intravascular devices [12]. It has been reported that thepredictors of in-hospital death were neurological abnormalities,
renal insufﬁciency, and staphylococcal IE [13,14]. In our study, age,
hemodialysis, congestive heart failure, and methicillin-resistant
staphylococcal IE (not staphylococcal IE) were the determinants of
in-hospital mortality by univariate analysis. The guidelines for IE
in Europe, the USA, and Japan recommend early surgical treatment
of IE as class I in cases of congestive heart failure and multi-drug
resistant organisms [24–26]. The present data may be concordant
with and supportive of these guidelines.
Composite events of in-hospital death and CNS disorders were
signiﬁcantly higher in the 2000s compared with those in the
1990s. A recent prospective randomized trial suggested that early
(within 48 h) surgical treatment decreased composite events of
in-hospital death and embolic events [21]. In addition, Kim et al.
reported that there was no signiﬁcant difference in in-hospital
death between early surgical treatment group and conservative
medical treatment group, while composite events of in-hospital
death and thromboembolism were signiﬁcantly lower in the early
surgical treatment group at 5-year follow-up [15]. Kang et al. also
reported that composite of in-hospital death, congestive heart fail-
ure, and systemic thromboembolism at 24-month follow-up was
signiﬁcantly lower in the surgical treatment group than in the con-
servative treatment group [21]. In our data, in-hospital death was
not signiﬁcantly different between the 1990s and 2000s, however,
surgical treatment with active IE was  signiﬁcantly less applied,
while the composite of in-hospital death and CNS disorders was
signiﬁcantly higher in the 2000s. Our study design was  a retro-
spective analysis and cannot conclude the association of surgical
treatment and clinical outcomes, however the above-mentioned
previous prospective randomized report [21] suggested early sur-
gical treatment might be able decrease CNS embolization compared
with conservative medical treatment.
Japanese guidelines recommend absolute indications (class I)
of surgical treatment for active IE are congestive heart failure
resistant to medical therapy and multi-drug resistant causative
organisms, while repeated embolism is a relative indication (class
IIa) [25]. Previous reports suggested that congestive heart failure
and multi-drug resistant causative organisms are determinants
of in-hospital mortality of IE, and that repeated embolism is a
determinant of composite events of in-hospital death and CNS
disorders [15,21]. Hemodialysis has been reported to be a deter-
minant of IE along with congestive heart failure and multi-drug
resistant causative organisms [13], which was conﬁrmed in our
study.
Study limitations
A retrospective study design with a relatively small sample
size in a single center may  pose a risk for patient selection bias.
Our study design cannot conclude the association of early surgi-
cal treatment and clinical outcome of CNS embolization because
of the observational study design; however, the prospective ran-
domized reports suggested early surgical treatment might be able
to decrease CNS embolization compared with conservative medi-
cal treatment. Our hospital is a referral and community hospital in
Japan, the results may not be generalizable to other communities.
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onclusions
In conclusion, the frequency of causative organisms of IE did not
hange between the 1990s and 2000s. Independent predictors of
n-hospital mortality in IE were hemodialysis and congestive heart
ailure.
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